Kempner Capital Management Cut Teva Phrm Ind LTD Adr (TEVA) Holding; Westport Asset Management Increased By $654,000 Its Check Point Software Technolog (CHKP) Stake

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Kempner Capital Management Inc decreased Teva Phrm Ind Ltd Adr (TEVA) stake by 63.06% reported in 2017Q4 SEC filing. Kempner Capital Management Inc sold 131,773 shares as Teva Phrm Ind Ltd Adr (TEVA)’s stock declined 11.04%. The Kempner Capital Management Inc holds 77,184 shares with $1.46M value, down from 208,957 last quarter. Teva Phrm Ind Ltd Adr now has $18.49 billion valuation. The stock increased 1.06% or $0.19 during the last trading session, reaching $18.18. About 9.16 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 13, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Westport Asset Management Inc increased Check Point Software Technolog (CHKP) stake by 34.68% reported in 2017Q4 SEC filing. Westport Asset Management Inc acquired 6,000 shares as Check Point Software Technolog (CHKP)’s stock declined 2.77%. The Westport Asset Management Inc holds 23,300 shares with $2.54M value, up from 17,300 last quarter. Check Point Software Technolog now has $16.78B valuation. The stock increased 0.90% or $0.92 during the last trading session, reaching $102.68. About 967,695 shares traded. Check Point Software Technologies Ltd. (NASDAQ:CHKP) has declined 4.45% since April 13, 2017 and is downtrending. It has underperformed by 16.00% the S&P500.

Among 32 analysts covering Check Point Software Technologies Ltd. (NASDAQ:CHKP), 5 have Buy rating, 1 Sell and 26 Hold. Therefore 16% are positive. Check Point Software Technologies Ltd. has $132 highest and $65 lowest target. $109.42’s average target is 6.56% above currents $102.68 stock price. Check Point Software Technologies Ltd. had 73 analyst reports since September 10, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, January 6 by Barclays Capital. The firm has “Market Perform” rating given on Thursday, January 5 by BMO Capital Markets. BTIG Research upgraded the shares of CHKP in report on Tuesday, February 7 to “Buy” rating. The rating was initiated by Robert W. Baird on Wednesday, August 24 with “Neutral”. The firm has “Hold” rating by BMO Capital Markets given on Thursday, June 1. Stifel Nicolaus maintained the shares of CHKP in report on Monday, July 17 with “Hold” rating. The company was downgraded on Wednesday, November 1 by Cowen & Co. The rating was downgraded by PiperJaffray to “Neutral” on Friday, July 21. The stock has “Hold” rating by RBC Capital Markets on Monday, May 29. Citigroup maintained Check Point Software Technologies Ltd. (NASDAQ:CHKP) rating on Wednesday, July 27. Citigroup has “Neutral” rating and $89 target.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.64 earnings per share, down 37.86% or $0.39 from last year’s $1.03 per share. TEVA’s profit will be $650.81 million for 7.10 P/E if the $0.64 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -29.67% negative EPS growth.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma has $86 highest and $8 lowest target. $28.73’s average target is 58.03% above currents $18.18 stock price. Teva Pharma had 149 analyst reports since July 21, 2015 according to SRatingsIntel. Mizuho maintained the stock with “Hold” rating in Wednesday, October 4 report. Credit Suisse upgraded the stock to “Neutral” rating in Friday, December 15 report. The firm has “Hold” rating by Guggenheim given on Wednesday, January 31. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Wednesday, November 29 with “Sell” rating. The firm has “Sell” rating by BTIG Research given on Monday, February 12. Morgan Stanley downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Monday, August 7. Morgan Stanley has “Underweight” rating and $16 target. The company was maintained on Wednesday, November 16 by Deutsche Bank. The rating was maintained by Mizuho on Wednesday, November 29 with “Hold”. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Wednesday, January 24. RBC Capital Markets has “Sell” rating and $13.0 target. Morgan Stanley maintained it with “Underweight” rating and $15 target in Thursday, October 5 report.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart